iX Biopharma wins Straits Times “Fastest Growing Companies 2026” accolade on back of WaferiX-driven revenue surge
Summary:
-
iX Biopharma has been named one of Singapore’s Fastest Growing Companies 2026 by The Straits Times and Statista, marking its third inclusion after earlier wins in 2023 and 2024.[links.sgx]
-
The ranking recognises strong multi‑year revenue growth and resilience, which the company attributes largely to its proprietary WaferiX sublingual drug delivery platform.[links.sgx]
-
iX Biopharma is pursuing a capital‑light expansion in the United States, targeting the longevity and wellness market via compounding pharmacy channels and potential collaborations for its Wafermine product.[links.sgx]
-
Management highlights plans to build a proprietary longevity‑focused digital platform, positioning the group for scalable, long‑term growth in its core therapeutic and wellness segments.[links.sgx]